Speaker illustration

Doctor Thomas A Zelniker

General Hospital Vienna, Medical University of Vienna, Vienna (Austria)

Member of:

European Society of Cardiology
Heart Failure Association

Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

Event: ESC CONGRESS 2019

Topic: Antidiabetic Pharmacotherapy

Session: New frontiers: SGLT2 inhibitors in cardiorenal disease

Thumbnail

ESC 365 is supported by

logo Novo Nordisk